Pei-Suen Tsou

Plain English
This study looked at a protein called RUNX1 in skin cells from patients with systemic sclerosis (SSc), an autoimmune disease that causes skin thickening. The researchers found that higher levels of RUNX1 are linked to more severe skin fibrosis, and skin cells with increased RUNX1 activity contribute to this thickening. They also discovered that reducing RUNX1 activity in lab tests lessened the problems associated with these skin cells, showing it could be a target for treatment. Who this helps: This research benefits patients with systemic sclerosis by identifying a potential new approach to managing skin fibrosis.

Plain English
In this study, researchers looked at a substance called soluble CD13 (sCD13) in patients with systemic sclerosis, a disease that can cause skin and organ fibrosis. They found that while sCD13 levels were higher in these patients compared to healthy individuals, they did not correlate with the severity of vascular issues or skin disease at baseline. However, in the early stages of the disease, higher levels of sCD13 indicated that patients were likely to see more improvement in skin fibrosis over the following year. Who this helps: This research can benefit patients with systemic sclerosis by providing insights into monitoring disease progression and treatment responses.

Plain English
This study investigated a specific genetic factor, NOTCH4, in African American patients with systemic sclerosis (SSc), a condition characterized by blood vessel problems and thickening of tissues. Researchers found that a certain gene variant was more common in African American patients with severe vascular issues—11% had the variant compared to fewer in other populations. Targeting the NOTCH4 pathway could help improve blood vessel growth and reduce tissue thickening, which are major problems for these patients. Who this helps: This research benefits African American patients with systemic sclerosis by identifying potential new treatments.

Plain English
This study looked at systemic sclerosis (SSc), a disease that causes thickening and scarring of the skin and other organs. Researchers found that a substance called PAI-1 is linked to the disease, and when they treated mice with a new drug called MDI-2517, it significantly reduced scarring in the skin and lungs, outperforming existing treatments. Specifically, MDI-2517 worked better at a much lower dose compared to another treatment, showing promise as a new way to help patients with SSc. Who this helps: Patients with systemic sclerosis.

Plain English
This study looked at the skin of patients with dermatomyositis (DM) and compared it to skin from lupus patients to understand what causes the skin issues in DM. Researchers found that certain immune cells and signals were more active in DM, leading to problems with blood vessel function in the skin; specifically, DM skin showed a large increase in specific signals and cell types. The findings suggest that blocking a specific pathway (JAK1) could help treat the difficult skin symptoms seen in DM patients, potentially improving their quality of life. Who this helps: This helps patients with dermatomyositis, especially those who struggle to manage their skin symptoms.

Plain English
This study focused on understanding how microvascular endothelial cells (MVECs) behave in patients with antiphospholipid syndrome (APS), a condition that can cause small blood vessels to become blocked. Researchers found that proteins called CCN1 and CCN2, which are involved in cell growth and movement, were increased in the skin and kidneys of APS patients. Specifically, they identified that exposure to antibodies from APS patients triggered these proteins, leading to increased activity in cells that form blood vessels. This research is important because it uncovers new targets for treatment, potentially helping to improve the health of people affected by APS. Who this helps: Patients with antiphospholipid syndrome and related vascular issues.

Plain English
This study looks at how blood vessel problems in systemic sclerosis (SSc) start with damage to the cells lining the blood vessels and lead to various health issues. Researchers found that changes in these cells can cause serious complications like painful finger swelling and high blood pressure in the lungs, which affect how patients feel and their quality of life. Understanding these issues better can help doctors find ways to diagnose and treat SSc more effectively, potentially improving patient outcomes. Who this helps: This helps patients with systemic sclerosis and their doctors.

Plain English
This study focused on dermatomyositis, an autoimmune disease that causes inflammation and skin problems. Researchers analyzed skin and blood samples from patients and found that immune cells in dermatomyositis exhibited specific patterns that differed from those in lupus, including increased levels of factors that lead to blood vessel damage. They discovered that blocking a protein called JAK1 could reduce this damage and improve skin symptoms. Who this helps: This helps patients with dermatomyositis, especially those whose skin conditions do not respond to current treatments.

Plain English
This study focused on a condition called systemic sclerosis (SSc), an autoimmune disease that leads to thickening and scarring of the skin. Researchers found that certain proteins (CD13 and B1 receptor) were more active in the skin of patients with a severe form of SSc, contributing to excessive scar formation. By blocking the B1 receptor, they were able to reduce the fibrosis-related responses in lab tests and in mice, showing that this approach could be a new way to treat SSc. Who this helps: This helps patients with systemic sclerosis and their doctors by potentially offering a new treatment option.

Plain English
This study looked at a substance called soluble CD13 (sCD13), which is produced during COVID-19 infections. Researchers found that patients with severe COVID-19 had much higher levels of sCD13, and this was linked to increased inflammation and complications. Specifically, elevated sCD13 levels were associated with heightened immune response processes that lead to blood vessel stress and clot formation. Who this helps: This research benefits COVID-19 patients and doctors by highlighting possible targets for new treatments.

Plain English
This study looked at systemic sclerosis (SSc), a serious autoimmune disease that causes thickening of the skin and internal organs due to excess fibrous tissue. Researchers found that both myofibroblasts and certain transitioning cells in the skin are major sources of this fibrous tissue, with a specific focus on the role of the Hippo signaling pathway in these cells. Understanding these processes could lead to new ways to reduce the fibrous tissue buildup in patients with SSc. Who this helps: This benefits patients with systemic sclerosis.

Plain English
This study explored how aging cells (senescent cells) contribute to tissue scarring (fibrosis) and diseases like systemic sclerosis (SSc). Researchers found that these aging cells play a significant role in both normal tissue repair and in conditions where the tissue becomes overly stiff and damaged, like SSc. By targeting these cells with new treatments (senolytics or senomorphs), there is potential for developing effective therapies for conditions characterized by fibrosis. Who this helps: Patients with systemic sclerosis and other fibrotic diseases.

Plain English
This research looked at how certain immune cells, called neutrophils, and their components, known as neutrophil extracellular traps, are connected to blood vessel problems in patients with systemic sclerosis (SSc). The study found that patients with vascular complications experienced higher levels of these traps, specifically noting that activating neutrophils and their traps was strongly linked to markers of blood vessel damage. Additionally, treating patients with a synthetic drug called epoprostenol reduced the levels of these traps and improved circulation. Who this helps: This research benefits patients with systemic sclerosis, particularly those facing vascular complications.

Plain English
This study focused on hidradenitis suppurativa (HS), a long-term skin condition that leads to painful lumps and scarring. Researchers discovered that certain types of skin cells, specifically two types of fibroblasts, play a significant role in HS and found that a signaling pathway called Hippo contributes to the excessive scarring seen in patients. By blocking the Hippo pathway, they showed that it may be possible to reduce fibrosis in HS, which could lead to new treatment options. Who this helps: This benefits patients with hidradenitis suppurativa seeking better treatment for their condition.

Plain English
This study examined how siponimod, a medication approved for treating a form of multiple sclerosis called secondary progressive MS (SPMS), protects brain cells from damage caused by inflammation. Researchers found that siponimod significantly reduced cell death triggered by the inflammatory substance TNF-alpha in both rat and human brain cells, suggesting it helps to keep brain cells alive during neuroinflammation. This matters because it could lead to better treatment options for progressive forms of MS, which currently have limited effective therapies. Who this helps: This helps patients with secondary progressive multiple sclerosis.

Plain English
This study investigated how a special antibody, UMCD6, affects immune cells that fight cancer. Researchers found that UMCD6 helps these immune cells, particularly natural killer (NK) cells and certain T cells, become more effective at killing cancer cells in mice with breast and prostate cancer, leading to improved survival rates. Specifically, treated mice had more powerful immune cells that were better positioned to attack tumors compared to those treated with a standard antibody. Who this helps: This benefits cancer patients by potentially improving treatments that enhance their immune responses to tumors.

Plain English
This study looked at a disease called systemic sclerosis (SSc), which causes hardening of the skin and organs, and found that patients with this condition have lower levels of a protein called SPAG17. Researchers discovered that when SPAG17 is reduced, it leads to a process where normal cells turn into myofibroblasts, which contribute to fibrosis (the thickening and scarring of tissue). In lab tests with mice, those missing SPAG17 developed significant skin fibrosis, showing that this protein plays a crucial role in preventing excessive scarring. Who this helps: This research can benefit patients with systemic sclerosis and similar fibrotic diseases by pointing to new treatment options.

Plain English
This study focused on a protein called TAK1, which plays a role in a serious condition called systemic sclerosis (SSc), known for causing harmful scarring in multiple organs. Researchers found that blocking TAK1 with a new drug, HS-276, not only stopped the formation of scar tissue in laboratory settings but also reversed existing scarring in animal models. This is significant because SSc currently has no effective treatments, and targeting TAK1 could lead to new options for managing this disease and other similar conditions. Who this helps: Patients with systemic sclerosis and other fibrotic diseases.

Plain English
This study focused on understanding pansclerotic morphea (PSM), a severe skin disease that causes extensive hardening and scarring of the skin. Researchers looked at skin samples from a patient over a year and found that a specific immune response involving certain cells was driving the disease. They discovered that targeting specific proteins involved in this immune response could lead to new treatment options. Who this helps: This helps patients with pansclerotic morphea by identifying potential new therapies.

Plain English
This study looked at a specific way to boost the immune system's ability to fight cancer by focusing on a molecule called CD6. Researchers found that using an antibody (UMCD6) to block the interaction between CD6 and a protein found on many cancer cells (CD318) led to better survival rates in mice with breast and prostate cancer. In these mice, more immune cells that attack tumors, like NK and CD8+ T cells, were present and more active compared to those that didn’t receive the treatment. Who this helps: This benefits cancer patients by potentially improving treatment outcomes.

Plain English
This study looked at how a herbal compound called cepharanthine (CEP) affects rheumatoid arthritis (RA) by targeting certain immune cells known as macrophages. The researchers found that CEP significantly reduced joint inflammation and damage in a mouse model of RA, lowering harmful substances like TNF-α and decreasing the number of M1 macrophages, which are linked to inflammation. This is important because it shows that CEP may offer a new way to treat RA, potentially helping patients manage their symptoms better. Who this helps: Patients with rheumatoid arthritis.

Plain English
This study looked at how a substance produced by gut bacteria, called trimethylamine N-oxide (TMAO), affects certain cells in the skin of patients with systemic sclerosis (SSc), a disease known for causing thickening of the skin and blood vessel damage. Researchers found that TMAO can turn normal skin cells into myofibroblasts, which are involved in tissue scarring, and that a specific protein called FMO3, which converts trimethylamine to TMAO, is increased in the skin of SSc patients. This connection between gut bacteria and skin inflammation could lead to new treatment options for SSc. Who this helps: This benefits patients with systemic sclerosis and potential treatment development.

Plain English
This paper studies how aging-related changes in cells, known as cellular senescence, are linked to systemic sclerosis (SSc), a disease that leads to hardening of the skin and organs. Researchers found that cellular senescence is important in the development of SSc, particularly affecting certain types of cells involved in blood vessel health and tissue formation. The research indicates that targeting these aging processes with new treatments could be a promising approach for managing SSc. Who this helps: Patients with systemic sclerosis may benefit from these new treatment options.

Plain English
This research studied the role of a protein called RP105 in a condition known as systemic sclerosis (SSc), which causes fibrous tissue buildup in the skin. The researchers found that lower levels of RP105 in the skin of SSc patients were linked to higher levels of TLR4, another protein that promotes fibrosis, and that removing RP105 worsened fibrosis in lab models. This matters because understanding how RP105 works could lead to new ways to treat or manage fibrosis in patients with SSc. Who this helps: This helps patients with systemic sclerosis.

Plain English
This study looked at the role of a gene called A20 and its regulator, DREAM, in systemic sclerosis (SSc), a disease that causes fibrosis, or thickening and scarring, in the skin and lungs. Researchers found that A20 levels are lower in the skin and lungs of SSc patients, while levels of DREAM are higher. In animal models, lacking A20 led to features of SSc, whereas animals without DREAM were protected, suggesting that targeting these genes might offer new treatments for fibrosis. Who this helps: Patients with systemic sclerosis and related fibrotic diseases.

Plain English
Researchers studied skin cells from patients with systemic sclerosis (SSc) to explore issues with centromeres, the part of chromosomes responsible for proper DNA distribution during cell division. They found that these cells had significant DNA damage and abnormal chromosome behavior, with 45% of diffuse cutaneous SSc patients showing a condition called aneuploidy, where cells have an abnormal number of chromosomes. These findings connect the problems with centromeres and chromosome instability to underlying autoimmune processes and tissue scarring in SSc, which can worsen patient symptoms and make treatment more complex. Who this helps: This helps patients with systemic sclerosis and their doctors by providing insights into the cellular causes of the disease.

Plain English
This study looked at how a protein called GPNMB behaves in the skin cells of patients with diffuse cutaneous scleroderma (dcSSc), a condition that causes skin thickening. Researchers found that the levels of GPNMB were higher in skin cells from dcSSc patients compared to healthy individuals, with notable levels of its soluble form measured at 147.4 pg/ml versus 84.8 pg/ml. This protein appears to help reduce cell activity that leads to fibrosis, suggesting that boosting GPNMB could be a new way to treat scleroderma. Who this helps: This benefits patients with scleroderma.

Plain English
This study looked at how blocking certain proteins called bromodomain extraterminal (BET) proteins can help reduce skin thickening in a condition known as scleroderma. The researchers found that using a drug called JQ1 to inhibit these proteins led to a significant reduction in fibrosis in lab animals and skin cells from scleroderma patients. Specifically, they observed changes in gene activity that affect cell growth and calcium levels, which are important for managing tissue fibrosis. Who this helps: This benefits patients with scleroderma by offering potential new treatment options.

Plain English
Researchers discovered that a protein called CD13, which leaks into the bloodstream, causes inflammatory arthritis by activating a receptor called B1R found on joint cells. They confirmed this by showing that blocking B1R with drugs stopped the inflammation in multiple types of arthritis in mice and in human joint tissue samples. This matters because B1R could be a new drug target to treat rheumatoid arthritis and other inflammatory diseases by preventing CD13 from triggering joint inflammation.

Plain English
This study focused on understanding how iloprost, a medication, helps improve blood vessel function in patients with scleroderma, a condition that often causes painful symptoms like Raynaud's phenomenon and skin ulcers. Researchers found that in patients with scleroderma, the junctions between cells that form blood vessels were weakened, making them less effective. Iloprost helped strengthen these junctions, which improved the cells' ability to work properly and reduced symptoms; specifically, it increased important protein levels (VE-cadherin) in the cells from an average of 29.7 to 37.3 fluorescence units. Who this helps: This research benefits patients with scleroderma suffering from Raynaud's phenomenon and digital ulcers.

Plain English
This study looked at how certain cells in the skin of patients with a condition called systemic sclerosis (SSc) behave differently compared to healthy individuals. Researchers found that the structure of DNA in skin cells (specifically endothelial cells and fibroblasts) from patients had significantly reduced accessibility, meaning it was less able to be read and used by the cell. This was linked to changes that may lead to problems with blood vessel formation and increased scar tissue in patients, which suggests new ways to treat this complex disease. Who this helps: This helps patients with systemic sclerosis and their doctors by offering new potential treatment targets.

Plain English
This study looked at how defibrotide, a drug already approved by the FDA, can protect blood vessel linings (endothelium) from damage caused by certain proteins released by immune cells. The researchers found that defibrotide effectively stopped harmful effects of these proteins, preventing cell activation and death, and protected against blood clots in mice. This matters because it shows that defibrotide could help treat various diseases linked to excessive inflammation and clotting. Who this helps: This helps patients suffering from conditions like autoimmunity, cancer, and COVID-19.

Plain English
This research studied how defibrotide, a drug approved by the FDA, can protect blood vessel linings from damage caused by harmful proteins released by neutrophils, a type of white blood cell. The researchers found that defibrotide can block these harmful proteins, reducing cell activation and death in lab tests, and it also helped prevent blood clots in mice. This is important because protecting the endothelium can help manage conditions like autoimmune diseases, cancer, and COVID-19, which are worsened by inflammation and blood clots. Who this helps: This benefits patients with conditions related to inflammation and blood clots, as well as doctors treating these patients.

Plain English
This research focuses on systemic sclerosis (SSc), a serious disease that causes inflammation and scarring in the skin and lungs. The study found that changes in certain chemical markers on DNA and proteins, known as epigenetic changes, play a significant role in how SSc develops. Understanding these changes could lead to new treatments that specifically target these processes, offering hope for better outcomes for patients with SSc. Who this helps: This helps patients suffering from systemic sclerosis.

Plain English
This research studied a new cancer treatment involving a specific antibody called UMCD6 that targets a protein known as CD6. The findings showed that UMCD6 significantly improved the ability of immune cells to kill breast, lung, and prostate cancer cells, leading to more effective cancer cell death than traditional treatments that block certain immune checkpoints. This is important because it not only enhances cancer killing but also helps control autoimmune responses, making it a promising new approach for cancer immunotherapy. Who this helps: This benefits cancer patients and doctors seeking more effective treatment options.

Plain English
This study focused on understanding how increased levels of a protein called EZH2 are related to higher energy production (glycolysis) and cellular signaling (mTORC1) in immune cells from patients with lupus, a chronic autoimmune disease. Researchers found that blocking glycolysis reduced EZH2 levels by restoring certain RNA molecules (miR-26a and miR-101) that normally help keep EZH2 in check. This matters because targeting these pathways could lead to new treatments that lower disease activity in lupus patients. Who this helps: This research benefits lupus patients by suggesting new ways to potentially manage their symptoms.

Plain English
This research paper examines a protein called GPNMB, which plays important roles in how cells function and respond to different conditions in the body. The study highlights how GPNMB is linked to various diseases, especially autoimmune disorders, and discusses its potential as a target for new treatments. Understanding GPNMB better could lead to improved therapies for conditions where the immune system attacks the body, which is crucial for enhancing patient care. Who this helps: Patients with autoimmune diseases.

Plain English
This study looked at the DNA changes in a specific type of immune cell, CD8+ T cells, from people with lupus compared to healthy individuals. Researchers found that lupus patients had 188 DNA sites that were less methylated than those in healthy controls, which affected the production of important immune-related proteins. This matters because it highlights how lupus CD8+ T cells respond differently to immune signals, possibly leading to worse disease symptoms and offering targets for new treatments. Who this helps: This helps patients with lupus and their doctors by identifying potential treatment targets.

Plain English
This study focused on scleroderma, a disease that causes thickening of the skin due to tissue fibrosis and blood vessel issues. Researchers found that blocking the EZH2 protein with a drug called DZNep reduced fibrosis and allowed normal blood vessel growth in lab experiments and animal models. Specifically, they showed that DZNep lowered harmful gene activity in scleroderma cells and improved blood vessel function by activating a cellular pathway involved in these processes. Who this helps: This research can benefit patients with scleroderma by offering new treatment options.

Plain English
This study looked at a protein called CYR-61 to see how it affects scleroderma, a disease that causes fibrosis or thickening of the skin and other tissues. Researchers found that higher levels of CYR-61 in skin cells from scleroderma patients reduced fibrosis-related gene activity and increased the production of helpful growth factors, with specific gene changes showing statistical significance (like COL1A1 dropping by P = 0.002). These findings suggest that boosting CYR-61 could slow down disease progression and help improve blood vessel growth in affected tissues. Who this helps: This benefits patients with scleroderma by potentially improving their treatment options.

Plain English
Researchers studied the effects of blocking a protein called EZH2 on lupus-like symptoms in mice. They found that using a drug called DZNep, which inhibits EZH2, improved the health of these mice by increasing survival rates and reducing harmful antibodies and inflammation. Specifically, DZNep treatment led to better kidney function and fewer signs of disease, showing promise for new lupus treatments. Who this helps: This research benefits lupus patients by suggesting potential new therapies.

Plain English
This study tested the drug riociguat to see if it could help people with systemic sclerosis who have painful finger sores known as digital ulcers. Researchers found that after 16 weeks, there was no significant difference in the number of ulcers between those taking riociguat and those taking a placebo; both groups had about 2.5 ulcers at the start and saw no major changes. However, in a follow-up phase, some patients who continued with riociguat showed complete healing of their ulcers, suggesting that longer treatment might be beneficial. Who this helps: Patients with systemic sclerosis and their doctors.

Plain English
This research paper looks at how changes in gene regulation, known as epigenetics, relate to systemic sclerosis (SSc), a disease that affects the skin and internal organs. Researchers found that these gene changes are present in immune cells and other cells from SSc patients, impacting important processes for the immune system and tissue growth. Understanding these changes is important because it could lead to new treatment options specifically designed for SSc patients. Who this helps: This helps patients with systemic sclerosis.

Plain English
This study focused on developing a new type of drug that can potentially help treat scleroderma, a condition that causes skin and connective tissue to become thick and stiff. Researchers discovered a new compound that was very effective at blocking a specific process in cells linked to this disease, achieving a strong impact at very low doses. The best candidates in this study significantly lowered fibrosis-related gene activity and helped reduce skin thickening in mouse models. Who this helps: This helps patients with scleroderma and doctors seeking new treatment options.

Plain English
This study looked at how caffeine affects immune cells in the blood, particularly in relation to autoimmune diseases like lupus and rheumatoid arthritis. The researchers found that high doses of caffeine significantly reduced the activity of inflammatory markers and genes associated with these diseases, with even a single cup of coffee lowering levels of important inflammatory substances like TNF and IL-6. This is important because it suggests caffeine might play a role in managing autoimmune conditions. Who this helps: Patients with autoimmune diseases who could benefit from dietary caffeine adjustments.

Plain English
This study looked at the role of a protein called MeCP2 in skin cells from patients with scleroderma, a disease that causes thickening and hardening of the skin. Researchers found that when MeCP2 levels were higher in these skin cells, it reduced their ability to grow and migrate, both of which contribute to the disease. Specifically, they discovered that certain genes influenced by MeCP2, like those for proteins PLAU and NID2, play important roles in fibrosis, suggesting that targeting these pathways could lead to new treatments. Who this helps: Patients with scleroderma could benefit from these findings as they may lead to new therapies.

Plain English
This study examined the role of a protein called interferon kappa (IFN-κ) in skin inflammation and sensitivity to sunlight in patients with cutaneous lupus. Researchers found that IFN-κ levels were about 1.5 times higher in the skin of lupus patients compared to healthy individuals, which made skin cells more responsive to inflammation and UV damage. This finding is important because targeting IFN-κ could lead to new treatments that help prevent skin problems in lupus patients. Who this helps: This helps patients with cutaneous lupus.